Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.54 |
| ▸ | HMGCR | P04035 | 3/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 3/20 | 0.48 |
| ▸ | PPARD | Q03181 | 3/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1050169 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL40510 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL2802414 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL20293445 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL2803510 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL2985078 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL740489 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL12680242 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL257132 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL29377936 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250324983-A1 | METHOD AND APPARATUS FOR CONTROLLING ARTHROPODS USING MASSOIA ESSENTIAL OIL AND RELATED PYRONES | US AGRICULTURE (US) | 2025-10-23 | — | — | US | claimed |
| CN-120136965-A | Isolated polypeptide of targeted MPP8 protein and application thereof | 苏州系统医学研究所 | 2025-06-13 | — | — | CN | claimed |
| WO-2025077276-A1 | REACTION SITE-CONTROLLABLE, LIGHT-INDUCED QUANTUM DOT PHOTOLITHOGRAPHY PATTERNING METHOD, AND APPLICATION THEREOF | 中国科学院宁波材料技术与工程研究所 | 2025-04-17 | — | — | WO | claimed |
| US-20230341376-A1 | SYSTEM, METHOD, AND COMPUTER-ACCESSIBLE MEDIUM FOR PHENOTYPING OF SINGLE CELLS WITH MULTIPLEXED VIBRATIONAL PROBES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-10-26 | — | — | US | claimed |
| WO-2021202997-A1 | SYSTEM, METHOD, AND COMPUTER-ACCESSIBLE MEDIUM FOR PHENOTYPING OF SINGLE CELLS WITH MULTIPLEXED VIBRATIONAL PROBES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-10-07 | — | — | WO | claimed |
| CN-111329850-A | Amino acid composition and application thereof in improving sleep disorder | 夏鹤春 | 2020-06-26 | — | — | CN | claimed |
| US-9480664-B2 | Compositions and methods for treating cancer | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2016-11-01 | — | — | US | claimed |
| US-9295667-B2 | Pharmaceutical composition for preventing or treating diabetes or fatty liver containing a CYP4A inhibitor as an active ingredient | KOREA BASIC SCIENCE INSTITUTE (KR) | 2016-03-29 | — | — | US | claimed |
| US-20140275198-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES OR FATTY LIVER CONTAINING A CYP4A INHIBITOR AS AN ACTIVE INGREDIENT | KOREA BASIC SCIENCE INSTITUTE (KR) | 2014-09-18 | — | — | US | claimed |
| US-7824866-B2 | Ligand for G-protein coupled receptor GPR72 and uses thereof | EUROSCREEN S.A. (BE) | 2010-11-02 | — | — | US | claimed |
| EP-1354200-B1 | METHOD OF SCREENING FOR GPR40 LIGANDS | GLAXO GROUP LTD (GB) | 2007-01-24 | — | — | EP | claimed |
| EP-1682153-A2 | METHODS OF MODULATING ANGIOGENESIS AND CANCER CELL PROLIFERATION | MCW Research Foundation, Inc. (US) | 2006-07-26 | — | — | EP | claimed |
| US-20050239807-A1 | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-10-27 | — | — | US | claimed |
| US-20050124618-A1 | Methods of modulating angiogenesis and cancer cell proliferation | HENRY FORD HEALTH SYSTEM | 2005-06-09 | — | — | US | claimed |
| WO-2005046658-A2 | METHODS OF MODULATING ANGIOGENESIS AND CANCER CELL PROLIFERATION | MCW RESEARCH FOUNDATION, INC. (US) | 2005-05-26 | — | — | WO | claimed |
| US-20250381245-A1 | METHODS AND COMPOSITIONS OF TREATING CANCER BY MODULATING PALMITOYLATION OF FLOTILLIN-1 | UNIV TEXAS (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250324983-A1 | METHOD AND APPARATUS FOR CONTROLLING ARTHROPODS USING MASSOIA ESSENTIAL OIL AND RELATED PYRONES | US AGRICULTURE (US) | 2025-10-23 | — | — | US | disclosed |
| WO-1998056348-A1 | COMPOSITIONS FOR DELIVERY OF BIOLOGICAL AGENTS AND METHODS FOR THE PREPARATION THEREOF | UNIVERSITY OF NEBRASKA BOARD OF REGENTS (US) | 1998-12-17 | — | — | WO | disclosed |
| WO-1998056334-A1 | COMPOSITIONS FOR DELIVERY OF BIOLOGICAL AGENTS AND METHODS FOR THE PREPARATION THEREOF | UNIVERSITY OF NEBRASKA BOARD OF REGENTS (US) | 1998-12-17 | — | — | WO | disclosed |
| WO-1998011049-A1 | LIPOXIN COMPOUNDS AND THEIR USE IN TREATING CELL PROLIFERATIVE DISORDERS | BRIGHAM & WOMEN'S HOSPITAL (US) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250324983-A1 | METHOD AND APPARATUS FOR CONTROLLING ARTHROPODS USING MASSOIA ESSENTIAL OIL AND RELATED PYRONES | AMY1A, MSMO1, CHIA | HSD17B10 804/4885CYP1A2 106/4885CYP2D6 2893/4885 |
| US-20050239807-A1 | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof | NOS1, SOD1, NOS3 | HSD17B10 1842/4885CYP1A2 759/4885CYP2D6 992/4885 |
| US-20140275198-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES OR FATTY LIVER CONTAINING A CYP4A INHIBITOR AS AN ACTIVE INGREDIENT | CYP4A11, CYP4A22, CYP7A1 | HSD17B10 121/4885CYP1A2 31/4885CYP2D6 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.